BEFORE YOU BEGIN
What to know.
- EGRIFTA SV has a specific indication involving HIV-related lipodystrophy.
- Its label states that it is not indicated for weight-loss management.
- The labeled safety and monitoring requirements still matter.
A clearer path through the details.
Use this reading map to jump to the questions covered below.
Keep the approved indication intact
The EGRIFTA SV prescribing information describes use to reduce excess abdominal fat in adults with HIV-related lipodystrophy. It says the product is not indicated for weight-loss management and notes that long-term cardiovascular safety has not been established.
This is a specific clinical setting. A marketing description about 'belly fat' does not establish that the same evidence applies to someone without that diagnosis. Ask the clinician to explain the proposed purpose in relation to the label.
Ask about the safety assessment
The label addresses concerns including increased IGF-1, glucose intolerance or diabetes, fluid retention, and hypersensitivity. It also identifies contraindications such as active malignancy, pregnancy, and certain disruptions of the hypothalamic-pituitary axis.
These are reasons to review the full prescribing information with a clinician rather than treating a brief peptide guide as a suitability assessment. Ask which concerns apply to your history and how follow-up would be arranged.
Distinguish the product from a broader claim
FDA's off-label guidance explains that prescribing an approved drug for a different purpose does not mean FDA has determined that it is safe and effective for that purpose.
Ask for the exact finished product, the purpose being proposed, and the evidence for any use beyond its label. This article does not supply reconstitution, administration, dose, or scheduling instructions and does not endorse a compounded preparation.
Sources: Understanding unapproved use of approved drugs (off label) · Resources for information on approved drugs
TAKE TO YOUR APPOINTMENT
Questions to ask.
- Does the proposed purpose match this product's approved indication?
- Which risks and contraindications apply to my history?
- What evidence supports any proposed use beyond the label?
- Who will review response and monitoring results?
FOLLOW THE EVIDENCE
Sources & further reading
- EGRIFTA SV (tesamorelin) prescribing informationNIH National Library of Medicine — DailyMed · Accessed October 3, 2026
- Understanding unapproved use of approved drugs (off label)U.S. Food and Drug Administration · Accessed October 3, 2026
- Resources for information on approved drugsU.S. Food and Drug Administration · Accessed October 3, 2026
EXPLORING CLINICAL CARE?
A separate next step.
If you explore clinical care information at Reform, ask its team about its scope and exact products. This link does not establish that tesamorelin is offered or that it is appropriate for general weight management.
Explore clinician-guided care information at ReformPrime Health directs interested readers to Reform. This care-service link is separate from our clinical sources. About this relationship.
